Programmed Death 1 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

63,053 results for “Programmed Death 1”

Trials

View all 37056 →

Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer

20 participants · First posted Dec 8, 2020

Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric

50 participants · First posted Jun 22, 2022

Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect

3 participants · First posted Jan 31, 2019

Drugs

View all 7279 →

GX-D1

Investigational

TTX-siPDL1

Programmed cell death 1 antibody(Sun Yat-Sen University)

Organizations

View all 1392 →

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

News

View all 17326 →

Advancements in Immune Checkpoint Inhibition for Hepatocellular Carcinoma Treatment

Indian Regulatory Committee Requests Protocol Revisions for Enzene's Nivolumab Biosimilar Phase III Trial

FDA Accepts Resubmission of NDA for Rivoceranib and Camrelizumab in Unresectable Hepatocellular Carcinoma

Page 1 of 6306